Skip to main content
PMC home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1998;6(1):38–43. doi: 10.1002/(SICI)1098-0997(1998)6:1<38::AID-IDOG8>3.0.CO;2-3

A review of famciclovir in the management of genital herpes.

S Faro 1
PMCID: PMC1784770  PMID: 9678146

Abstract

The frequent occurrence of genital herpes continues to be a serious clinical problem. Although not life threatening, the physical symptoms of the disease, and the ensuing psychosocial complications, can be overwhelming to patients. The life cycle of the herpes simplex virus is complex, comprising multiple stages. Following infection, the virus establishes life-long latency in its host and can reactivate at any time as a recurrent infection. Successful management of genital herpes simplex infections involves patient education and psychological support, as well as antiviral agents. The antiviral agent famciclovir has been shown to shorten the course and decrease the severity of episodes of recurrent genital herpes. In addition, famciclovir has been shown to be effective in suppressing recurrent genital herpes. A review of the clinical experience with famciclovir in the treatment of genital herpes is presented.

Full Text

The Full Text of this article is available as a PDF (502.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benedetti J., Corey L., Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994 Dec 1;121(11):847–854. doi: 10.7326/0003-4819-121-11-199412010-00004. [DOI] [PubMed] [Google Scholar]
  2. Boyd M. R., Bacon T. H., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother. 1987 Aug;31(8):1238–1242. doi: 10.1128/aac.31.8.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Catotti D. N., Clarke P., Catoe K. E. Herpes revisited. Still a cause of concern. Sex Transm Dis. 1993 Mar-Apr;20(2):77–80. [PubMed] [Google Scholar]
  4. Corey L., Adams H. G., Brown Z. A., Holmes K. K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983 Jun;98(6):958–972. doi: 10.7326/0003-4819-98-6-958. [DOI] [PubMed] [Google Scholar]
  5. Corey L., Spear P. G. Infections with herpes simplex viruses (1). N Engl J Med. 1986 Mar 13;314(11):686–691. doi: 10.1056/NEJM198603133141105. [DOI] [PubMed] [Google Scholar]
  6. Earnshaw D. L., Bacon T. H., Darlison S. J., Edmonds K., Perkins R. M., Vere Hodge R. A. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992 Dec;36(12):2747–2757. doi: 10.1128/aac.36.12.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fleming D. T., McQuillan G. M., Johnson R. E., Nahmias A. J., Aral S. O., Lee F. K., St Louis M. E. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997 Oct 16;337(16):1105–1111. doi: 10.1056/NEJM199710163371601. [DOI] [PubMed] [Google Scholar]
  8. Hodge R. A., Perkins R. M. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother. 1989 Feb;33(2):223–229. doi: 10.1128/aac.33.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Landy H. J., Grossman J. H., 3rd Herpes simplex virus. Obstet Gynecol Clin North Am. 1989 Sep;16(3):495–515. [PubMed] [Google Scholar]
  10. Lavery H. A., Connolly J. H., Russell J. D. Incidence of herpes genitalis in Northern Ireland in 1973-83 and herpes simplex types 1 and 2 isolated in 1982-4. Genitourin Med. 1986 Feb;62(1):24–27. doi: 10.1136/sti.62.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mertz G. J., Loveless M. O., Levin M. J., Kraus S. J., Fowler S. L., Goade D., Tyring S. K. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med. 1997 Feb 10;157(3):343–349. [PubMed] [Google Scholar]
  12. Sacks S. L., Aoki F. Y., Diaz-Mitoma F., Sellors J., Shafran S. D. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA. 1996 Jul 3;276(1):44–49. [PubMed] [Google Scholar]
  13. Saltzman R., Jurewicz R., Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994 Oct;38(10):2454–2457. doi: 10.1128/aac.38.10.2454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Straus S. E., Rooney J. F., Sever J. L., Seidlin M., Nusinoff-Lehrman S., Cremer K. NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention. Ann Intern Med. 1985 Sep;103(3):404–419. doi: 10.7326/0003-4819-103-3-404. [DOI] [PubMed] [Google Scholar]
  15. Thackray A. M., Field H. J. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis. 1996 Feb;173(2):291–299. doi: 10.1093/infdis/173.2.291. [DOI] [PubMed] [Google Scholar]
  16. Tyring S., Barbarash R. A., Nahlik J. E., Cunningham A., Marley J., Heng M., Jones T., Rea T., Boon R., Saltzman R. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995 Jul 15;123(2):89–96. doi: 10.7326/0003-4819-123-2-199507150-00002. [DOI] [PubMed] [Google Scholar]
  17. Vere Hodge R. A., Darlison S. J., Readshaw S. A. Use of isotopically chiral [4'-13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. Chirality. 1993;5(8):577–582. doi: 10.1002/chir.530050803. [DOI] [PubMed] [Google Scholar]
  18. Vere Hodge R. A., Sutton D., Boyd M. R., Harnden M. R., Jarvest R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989 Oct;33(10):1765–1773. doi: 10.1128/aac.33.10.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]
  20. Whitley R. J., Gnann J. W., Jr Acyclovir: a decade later. N Engl J Med. 1992 Sep 10;327(11):782–789. doi: 10.1056/NEJM199209103271108. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES